Effects of local delivery of bFGF from PLGA microspheres on osseointegration around implants in diabetic rats

Zou, Guike; Song, Yingliang; Zhou, Wei; Yu, Miao; Liang, Lihua; Sun, Dongdong; Li, Dehua; Deng, Zaixi; Zhu, Wei

doi:10.1016/j.tripleo.2011.07.006

Cited by 36 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For these studies, the use of fibroblast growth factor-2 (FGF-2) has been well documented. Utilization of polymer-based particle as a carrier to deliver FGF-2, such as poly(lactide-coglycolide) microspheres reported for titanium implant [82], may be applied for resin-based restoratives. Few trials have been reported regarding the delivery of growth factors from dental resins.…”

Section: Addition Of Growth Factorsmentioning

confidence: 99%

Therapeutic polymers for dental adhesives: Loading resins with bio-active components

et al. 2014

View full text Add to dashboard Cite

Objectives Many recent adhesives on the market exhibit reasonable clinical performance. Future innovations in adhesive materials should therefore seek out novel properties rather than simply modifying existing technologies. It is proposed that adhesive materials that are “bio-active” could contribute to better prognosis of restorative treatments. Methods This review examines the recent approaches used to achieve therapeutic polymers for dental adhesives by incorporating bio-active components. A strategy to maintain adhesive restorations is the focus of this paper. Results Major trials on therapeutic dental adhesives have looked at adding antibacterial activities or remineralization effects. Applications of antibacterial resin monomers based on quaternary ammonium compounds have received much research attention, and the loading of nano-sized bioactive particles or multiple ion-releasing glass fillers have been perceived as advantageous since they are not expected to influence the mechanical properties of the carrier polymer. Significance The therapeutic polymer approaches described here have the potential to provide clinical benefits. However, not many technological applications in this category have been successfully commercialized. Clinical evidence as well as further advancement of these technologies can be a driving force to make these new types of materials clinically available.

show abstract

Section: Addition Of Growth Factorsmentioning

confidence: 99%

Therapeutic polymers for dental adhesives: Loading resins with bio-active components

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In addition, high doses of bFGF can lead to adverse side effects, including thrombocytopenia, renal toxicity, and malignant cell activation . Due to these properties, bFGF should ideally be used in combination with a carrier to promote retention at wound sites . Although a number of different natural and synthetic carriers for bFGF have been evaluated, currently available carriers are restricted to demineralized bone matrix (DBM) and collagen, and are therefore the most frequently used scaffolds for bone repair in the clinical setting.…”

Section: Introductionmentioning

confidence: 99%

Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen‐binding domain from Clostridium histolyticum collagenase

Uchida

Matsushita

Naruse

et al. 2013

J Biomedical Materials Res

View full text Add to dashboard Cite

Basic fibroblast growth factor 2 (bFGF) is a potent mitogen for mesenchymal cells, and the local application of recombinant bFGF accelerates bone union and defect repair. However, repeated dosing is required for sustained therapeutic effect as the efficacy of bFGF decreases rapidly following its diffusion from bone defect sites. Here, we attempted to develop a collagen-based bone formation system using a fusion protein (collagen binding-bFGF, CB-bFGF) consisting of bFGF and the collagen-binding domain (CBD) of Clostridium histolyticum collagenase. The addition of the CBD to bFGF did not modify its native biological activity, as shown by the capacity of the fusion protein to promote the in vitro proliferation of periosteal mesenchymal cells. The affinity of the fusion protein towards collagen and demineralized bone matrix (DBM) was also confirmed by collagen-binding assays. Moreover, in vivo periosteal bone formation assays showed that the combination of CB-bFGF with a collagen sheet induced periosteal bone formation at protein concentrations lower than those required for bFGF alone. In addition, grafts of DBM loaded with CB-bFGF accelerated new bone formation in rat femurs compared to the same concentration of bFGF administered alone. Taken together, these properties suggest that the CB-bFGF/collagen composite is a promising material for bone repair in the clinical setting. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 1737–1743, 2014.

show abstract

“…As one class of protein drugs, basic broblast growth factor (bFGF) is essential for tissue regeneration due to its promotion of cellular growth and participation in the regulation of tissue repair processes. 3,4 However, bFGF is very sensitive to enzymes in vivo, and could be degraded and cleared from the body within short time periods. It would lead to structural disruption and bioactivity loss when bFGF was administered in vivo.…”

Section: Introductionmentioning

confidence: 99%

The effect of crosslinking agent on sustained release of bFGF–collagen microspheres

Liu

Dan

2015

RSC Adv.

View full text Add to dashboard Cite

Initial burst release and loss of bioactivity of drugs are the shortcomings of drug delivery systems (DDSs) used for in vivo treatment. Therefore, in this context, hydrophilic collagen was chosen as the carrier material for basic fibroblast growth factor (bFGF) and collagen microspheres were crosslinked by carbodiimide (EDC) in different concentrations. Collagen microspheres were characterized by a mastersizer, scanning electron microscope (SEM), differential scanning calorimetry (DSC) analysis, determination of free amino test and methyltetrazolium (MTT) test due to reveal their particle size and distribution, surface morphology, thermodynamic properties, crosslinking degree and biocompatibility.The effect of crosslinking agent on the release kinetics of bFGF-collagen microspheres was studied systematically in detail. The results demonstrate that the crosslinking agent concentration has some influence on the release of collagen microspheres and has the potential to reduce initial drug burst release and control the release rate. This study provides an opportunity for preparing bFGF-collagen microspheres for application in the DDS field.

show abstract

Effects of local delivery of bFGF from PLGA microspheres on osseointegration around implants in diabetic rats

Cited by 36 publications

References 26 publications

Therapeutic polymers for dental adhesives: Loading resins with bio-active components

Therapeutic polymers for dental adhesives: Loading resins with bio-active components

Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen‐binding domain from Clostridium histolyticum collagenase

The effect of crosslinking agent on sustained release of bFGF–collagen microspheres

Contact Info

Product

Resources

About